DETECTION-2
Research type
Research Study
Full title
DETECTION-2 feasibility: A feasibility trial to assess recruitment rates and ctDNA reporting times for patients with resected stage IIB/IIC/IIIA melanoma
IRAS ID
341779
Contact name
Paul Lorigan
Contact email
Sponsor organisation
The Christie NHS Foundation Trust
ISRCTN Number
ISRCTN13695430
Duration of Study in the UK
6 years, 9 months, 31 days
Research summary
We are looking for new and better ways to manage melanoma, an aggressive type of skin cancer. Surgery to remove the melanoma will cure the majority of patients with early stage disease. However, a small percentage of these patients will go on to develop further disease, which may spread to other places in their body. At present, following surgery, patients with early stage melanoma can either choose to have close monitoring with regular scans and skin checks or they can have a year of drug treatment. This study is testing whether we can follow patients with regular ctDNA (circulating tumour DNA found in blood) tests and only treat those patients that become ctDNA positive indicating disease activation. Thus reduce the amount of unnecessary drug treatment and potential side effects for patients by using ctDNA testing . This test can identify early melanoma relapse when it is not visible on imaging. Patients will remain in the study for at least 5 years and will be seen in hospital clinics.
REC name
Yorkshire & The Humber - Sheffield Research Ethics Committee
REC reference
24/YH/0142
Date of REC Opinion
10 Jul 2024
REC opinion
Favourable Opinion